Prenetics Global (NASDAQ:PRE) co-founder and CEO Danny Yeung said the company is now centered on its IM8 supplement business after divesting non-core operations over the past 12 to 18 months, pointing to rapid early growth since IM8’s launch in December 2024.
Positioning IM8 in a competitive market
Yeung described IM8 as entering a “very competitive” supplement category where many advised against launching due to the crowded landscape and limited regulation. He said the company’s approach relied on pairing a “great product” with strong brand awareness and distribution, aided by having David Beckham as a co-founder to “cut through the noise” from a PR and messaging standpoint.
Product development, testing, and certifications
Yeung said IM8’s formulation took roughly a year and a half to develop and was supported by a scientific advisory board that included Dr. Dawn Mussallem of Mayo Clinic and Suzanne Devkota of Cedars-Sinai, among others. He also emphasized steps taken to support quality and credibility, including:
- A 12-week randomized case-control trial conducted with the San Francisco Research Institute prior to launch
- NSF Certified for Sport certification
- Third-party testing from Eurofins
Yeung said the company makes research results and reports available for download on its website. He also noted that IM8 includes “90+ ingredients” and that each ingredient on the label is third-party tested, saying the testing verifies that stated ingredient quantities match what is delivered.
On athlete adoption, Yeung cited Aryna Sabalenka, the world’s No. 1 women’s tennis player, saying she took the product for three months before contacting the company. He also said IM8 recently signed Ollie Bearman, an F1 driver, and that Bearman’s team is using the product.
Growth milestones and international reach
Yeung outlined a timeline of growth since launch. He said IM8 began selling online in December 2024 and generated $581,000 in revenue in its first month. In January, the company held a public launch in New York, and Beckham appeared on the TODAY show to promote the product, which Yeung said drove PR and media exposure.
He said the company saw an uplift in June after bringing on Sabalenka, describing the partnership as organic and driven by her performance coach’s experience with the product. In October, IM8 launched its second SKU, a Longevity product, which Yeung said increased average order value from $110 to $150 “overnight.” By December 2025, he said IM8 reached $10 million in monthly revenue.
Yeung said IM8 shipped to 31 countries from the outset, calling it logistically difficult but strategically important. He said the U.S. represented about 40% of overall revenue, with Canada, the U.K., Australia, and Singapore among the next largest markets. Yeung said the business is “100% online,” with 98% of sales on IM8’s own website and about 2% on Amazon, where he said pricing is intentionally higher to steer consumers to the company’s site and customer journey.
Yeung said full-year revenue in 2025 totaled $60 million, including $25 million in the U.S. He added that, in his view, the U.S. “can easily do $150 million–$200 million” at scale.
2026 outlook, marketing engine, and new SKUs
Looking to 2026, Yeung said momentum has continued into the first quarter and that the company is confident in its projection of $180 million to $200 million for 2026. He attributed growth in part to a content-driven social advertising strategy, stating IM8 runs about 2,200 Meta ads at any given time and uses roughly 50 landing pages tailored to different consumer personas.
On product expansion, Yeung said the company is being deliberate about adding SKUs to avoid diluting the brand message and because developing best-in-class products requires significant work. He said two additional SKUs are planned for launch by Q4, aimed at “very large” total addressable markets, but noted they were not included in 2026 guidance.
Retention targets, unit economics, and capital allocation
On customer performance, Yeung said repeat purchases are a majority of revenue and argued that rapid growth to $100 million in annual recurring revenue would not be possible without strong retention. He said IM8 is targeting 12-month retention of roughly 25% to 30%, compared with what he described as typical supplement-category retention “in the teens.”
He also discussed evolving subscription options. Yeung said that for much of 2025, IM8 offered one-time purchases and a monthly subscription, which he described as $112 for a one-time purchase in the U.S. and $89 for monthly renewal. In December, the company introduced a three-month program, lowering the monthly subscription price to $78 with $235 paid upfront. Yeung said the three-month option helps because customers commit for a longer period, shipping is consolidated, and revenue can be recognized when three months’ product is shipped.
On unit economics, Yeung cited an industry benchmark of a 3:1 LTV-to-CAC ratio over 24 months. He said IM8 is currently around that level, with customer acquisition cost of roughly $220 to $230, average order value around $200, and lifetime value around $660 to $670.
Yeung also addressed a recently announced $40 million share repurchase plan and executive open-market buying. He said the leadership team believes the public company has been undervalued and cited what he described as strong brand momentum. Yeung said executives have purchased $2.75 million in total, including $1.25 million of his own funds. He also said the company had $160 million in liquid assets.
In response to a question about China, Yeung said he has spoken with potential partners and sees “significant upside opportunity,” but emphasized the company is not rushing entry and is taking a strategic approach. He said many U.S. companies fail in China by attempting to import products without proper localization. He added that IM8’s ambassadors—including Beckham and Sabalenka—are well-liked in China, which he believes could be advantageous when the company decides the time is right.
Finally, Yeung said the company is using AI tools to scale its marketing operation, arguing that effective use requires “focused attention” and constant testing across creative, landing pages, and conversion metrics. He said that refining this approach is part of a plan to reach profitability by Q4 2027.
About Prenetics Global (NASDAQ:PRE)
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
